To order this 170+ page report, please visit
this
- https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html
Key
Inclusions
§
A detailed review of the overall landscape of fragment-based drug discovery library and
service providers along with the information on type of product (library and
technology), type of service offered (fragment screening and fragment
optimization), type of technique used (X-ray crystallography, nuclear magnetic
resonance, surface plasmon resonance, and other screening techniques), other
services offered (target identification / validation, hit identification,
hit-to-lead / lead generation, lead optimization), and end user (industry, academia,
and contract research organizations).
§
Elaborate profiles of
the companies providing libraries and services for fragment-based drug
discovery (shortlisted on the basis of the service portfolio and number of
fragment screening techniques offered). Each profile features a brief overview
of the company, its financial information (if available), fragment-based
library and service portfolio, information on other drug discovery services,
recent developments and an informed future outlook.
§
An analysis of the partnerships
that have been established in the recent past, covering R&D collaborations,
mergers and acquisitions, product development and commercialization agreements,
commercialization agreements, distribution and supply agreements, product
integration agreements, service agreements, and other relevant types of deals.
§
A detailed analysis
on acquisition targets, taking into consideration the historical trend of the
activity of the companies that have acquired other firms since 2015, and
offering a means for other industry stakeholders to identify potential
acquisition targets.
§
An insightful
competitiveness analysis of fragment-based drug discovery library and service
providers, based on supplier power (based on the years of experience of service
provider) and key specifications, such as number of fragment libraries and
number of screening techniques.
§
An analysis
highlighting the cost saving potential associated with the use of
fragment-based drug discovery approach.
§
Informed estimates of the existing
market size and the future opportunity for fragment-based drug discovery
library and services, over the next decade. Based on multiple parameters, such
as annual number of drug discovery projects, outsourcing profile, and adoption
of fragment-based drug discovery approach, we have provided informed estimates
on the evolution of the market for the period 2020-2030.
The report features the likely distribution of the
current and forecasted opportunity across important market segments, mentioned
below:
§
Type of Screening
Technique Used
§
X-ray Crystallography
§
Nuclear Magnetic
Resonance
§
Surface Plasmon
Resonance
§
Other Screening
Techniques
§
Type of Service
Offered
§
Library Screening
§
Fragment Screening
§
Fragment Optimization
§
End User
§
Industry Players
§
Non-Industry Players
§
Key geographical
regions
Press Release: Variation 4 (Format 5)
§
North America (US and
Canada)
§
Europe (UK, France,
Germany, Spain, Italy, and rest of Europe)
§
Asia-Pacific (China,
Japan, India, and rest of Asia-Pacific / rest of the world)
The report also
features inputs from eminent industry stakeholders, according to whom the
fragment-based approach significantly simplifies the drug discovery process.
The report includes detailed transcripts of discussions held with the following
experts:
§
Jean-Yves Ortholand
(Co-founder and Chief Executive Officer, Edelris)
§
Björn Walse (Chief
Executive Officer, SARomics Biostructures)
To request sample
pages, please visit this- https://www.rootsanalysis.com/reports/309/request-sample.html
Key Questions Answered
§
Who are the leading
players in the fragment-based drug discovery library and services market?
§ What are the key biophysical techniques used by service
providers for screening fragment libraries and lead optimization?
§ Which types of partnership models are commonly adopted by
stakeholders in this domain?
§ What is the likely cost-saving opportunity associated with
the use of fragment-based drug discovery?
§
How is the current
and future market opportunity likely to be distributed across key market
segments?
You may also be
interested in the following titles:
1.
DNA-Encoded
Libraries: Platforms and Services
Market
2.
Antibody
Discovery: Services and Platforms Market (2nd Edition),
2018-2028
3.
In
Silico / Computer-Aided Drug Discovery Services
Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid,
Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery,
Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug
Discovery, Interface Based Drug Discovery Approaches)
Contact Us:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
